<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05041946</url>
  </required_header>
  <id_info>
    <org_study_id>2003-0537</org_study_id>
    <nct_id>NCT05041946</nct_id>
  </id_info>
  <brief_title>Patient Controlled Methylphenidate for Cancer Related Fatigue: A Double Blind, Randomized, Placebo Controlled Trial</brief_title>
  <official_title>Patient Controlled Methylphenidate for Cancer Related Fatigue: A Double Blind, Randomized, Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the effectiveness of patient controlled methylphenidate as compared to placebo&#xD;
      for the management of cancer related fatigue as determined by the Functional Assessment of&#xD;
      Chronic Illness Therapy (FACIT)-F Fatigue score.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective:&#xD;
&#xD;
      -To determine the effectiveness of patient controlled methylphenidate as compared to placebo&#xD;
      for the management of cancer related fatigue as determined by the Functional Assessment of&#xD;
      Chronic Illness Therapy (FACIT)-F Fatigue score&#xD;
&#xD;
      Secondary objective&#xD;
&#xD;
        -  To assess the efficacy of as needed methylphenidate on pain, sedation and quality of&#xD;
           life.&#xD;
&#xD;
        -  To assess the potential side effects of methylphenidate on appetite, insomnia and&#xD;
           anxiety&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 16, 2003</start_date>
  <completion_date type="Anticipated">July 16, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 16, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To establish the effectiveness of patient the management of cancer related fatigue as determined by the Functional Assessment of Chronic Illness Therapy (FACIT)-F Fatigue score: 0-10 numerical scale.</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Fatigue</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Methylphenidate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>treatment of attention deficit disorder and narcolepsy (sleep disorder)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sugar pill</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylphenidate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Methylphenidate</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo (Sugar Pill)</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Methylphenidate</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Presence of fatigue on a numerical scale during the last 24 hours of more or equal to&#xD;
             4 on a 0 to 10 scale in which 0 equals no fatigue and 10 worst possible fatigue.&#xD;
&#xD;
          -  Patients should describe fatigue as being present for a minimum of four days.&#xD;
&#xD;
          -  If patients are on opioids for the treatment of cancer pain, change of opioids is&#xD;
             allowed.&#xD;
&#xD;
          -  No clinical evidence of cognitive failure, with normal Mini Mental State Examination&#xD;
             (MMSE). A score of 24 is considered as normal.&#xD;
&#xD;
          -  Sign written informed consent.&#xD;
&#xD;
          -  Patients must be 18 years or older.&#xD;
&#xD;
          -  Patient willing to keep a daily diary, engage in daily telephone follow up with a&#xD;
             nurse, and after 7 days of treatment patient will return for a follow up visit.&#xD;
&#xD;
          -  Patient must have telephone access to be contacted daily by the research nurse.&#xD;
&#xD;
          -  Hemoglobin of &gt;/=10 g/dl within 2 weeks of enrollment. If the patient has not had&#xD;
             blood drawn for a hemoglobin level in the past two weeks, one will be done to&#xD;
             determine the eligibility.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Major contraindication to methylphenidate i.e. hypersensitivity, anxiety, tension,&#xD;
             agitation, or motor tics&#xD;
&#xD;
          -  Currently on methylphenidate or has been on methylphenidate within the last 10 days.&#xD;
&#xD;
          -  Inability to complete the baseline assessment forms or to understand the&#xD;
             recommendations for participation in the study.&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Patients taking MAO inhibitors, tricyclic antidepressants and clonidine.&#xD;
&#xD;
          -  Patients with glaucoma, history of marked anxiety disorder, or history of substance&#xD;
             abuse.&#xD;
&#xD;
          -  CAGE questionnaire score for the last 2 years is 2 or above on a 0 to 4 scale&#xD;
&#xD;
          -  History of Tourette's syndrome&#xD;
&#xD;
          -  Patients with tachycardia and uncontrolled hypertension.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eduardo Bruera</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>M D Anderson Cancer Center</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 3, 2021</study_first_submitted>
  <study_first_submitted_qc>September 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2021</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylphenidate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

